Associated Papers
Sensorineural hearing loss in anti-interleukin-1 treated CAPS patients: risk factors and real-life barriers-an observational study.
Satirer Ö et al.
Rheumatology (oxford, England), 2025
Dysregulation of inflammasomes in autoinflammatory diseases.
Hou C et al.
Joint Bone Spine, 2025
Novel Insights into the Clinical Features, Genetic Spectrum and Clonal Evolution of Patients Carrying NLRP3 Mosaicism.
Bonet N et al.
Journal of Clinical Immunology, 2025
The RNA degradation enzyme RNase E is essential for early flagellar assembly in Escherichia coli.
Wang WS et al.
Pnas Nexus, 2025
40894857 (PubMed )
Supplement: pgaf269_supplementary_data.docx
Genetic landscape of Romanian children with inborn errors of immunity via gene panels, exome, and genome sequencing.
Pantea CL et al.
Scientific Reports, 2025
Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants.
Feng S et al.
Nature Immunology, 2025
Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome: From action mechanism to therapeutic target in clinical trials.
Zhang CY et al.
World Journal of Gastrointestinal Oncology, 2025
The role of gene mutations and immune responses in sensorineural hearing loss.
Zhang X et al.
International Immunopharmacology, 2024
Pregnancy occurring in AA amyloidosis: a series of 27 patients including 3 new French cases.
Delplanque M et al.
Journal of Nephrology, 2024
Novel chemotype NLRP3 inhibitors that target the CRID3-binding pocket with high potency.
Vande Walle L et al.
Life Science Alliance, 2024
Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation.
Cosson C et al.
The Journal of Experimental Medicine, 2024
1–50 of 205 papers
Select a paper to view details